crown lengthing surgery.
Conditions
Interventions
Intervention 1: Intervention group: rinse with benzydamine hydrochloride mouthwash 0.15% (the pharmaceutical company "Exir" Boroujerd) at a rate of once every 3 hours 15 ml for 30 seconds in mouth. In
Treatment - Drugs
Intervention group: rinse with benzydamine hydrochloride mouthwash 0.15% (the pharmaceutical company "Exir" Boroujerd) at a rate of once every 3 hours 15 ml for 30 seconds in mouth.
Control group: consume ibuprofen 400 mg tablets every 6 hours (the pharmaceutical company "Hakim").
Sponsors
Vice Chancellor for research of Shahid Sadooghi University Of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Periodontal health establishment? require crown lengthening surgery in the posterior teeth? avoiding the use of any painkiller or anti-inflammatory or Counter during the last 6 months? lack of systemic problems? lack of contraindications of ibuprofen or Benzydamine hydrochloride mouthwash. Benzydamine hydrochloride contraindications include hypersensitivity to the drug or formulation components? children under 12 years of age? past medical history and feed intake. Warning of eye contact with the drug. The classification used in pregnancy? is in category C. It should not be administered to a patient more than 7 days? and in case of allergies? medication should be discontinued. Information on medication safety in nursing mothers. Contraindications Ibuprofen include third trimester of pregnancy (the drugs X)? such as anaphylaxis or Angioedema history of severe allergic reaction caused by aspirin or other non steroidal anti-inflammatory drugs or nose polyp with spasticity due to an inflammatory disease or ulcerative the upper or lower gastrointestinal tract ? hemophilia and other blood disorders? including disorders of hemostasis? or platelets? kidney disorders ? stomatitis and elderly patients and patients the risk of gastrointestinal bleeding and ulcers in them is high. Concomitant use of ibuprofen with inhibitors of angiotensin converting enzyme (ACE)? one of the quinolone antibacterial agents? hypoglycemic sulfonylurea drugs? cyclosporine? lithium and methotrexate may? anticoagulants or thrombolytic? triamterene? valproic acid? aspirin and performance they interference is increasing or decreasing. Exclusion criteria: Unwillingness to participate in the plan? effective pain medications (analgesics or anti-inflammatory drug or drug) during the last 6 months? the risk of systemic problems affecting the periodontal tissues (diabetes? hypertension and heart disease? vascular)? ibuprofen is contraindicated or mouthwash Benzydamine hydrochloride.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: 24 hours after intervention. Method of measurement: Visual Analog Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Stingling & numbness. Timepoint: 24 hours after intervention. Method of measurement: asking from patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArezoo Khbazian
Shahid Sadooghi University Of Medical Sciences
Outcome results
None listed